Immunome Completes Purchase of AL102, Related Drug Candidate AL101 From Ayala Pharmaceuticals >IMNM
Immunome Completes Purchase of AL102, Related Drug Candidate AL101 From Ayala Pharmaceuticals >IMNM
Dow JonesMar 26 08:01 ET
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced s
GlobeNewswireMar 26 08:00 ET
Ayala Completes Patient Enrollment for Pivotal Desmoid Tumor Study
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, has announced the completion of patient enrollment for its Phase 3 RINGSIDE study, which is evaluating the efficacy of the drug AL102 in treating desmoid tumors.
Investing.com Feb 20 10:32 ET
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment h
GlobeNewswireFeb 20 08:00 ET
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating.
MT NewswiresFeb 7 08:53 ET
Advaxis Announces Definitive Agreement With Ayala Pharmaceuticals
TipRanksFeb 7 04:17 ET
Express News | Immunome Shares Are Trading Higher After the Company Announced That It Entered Into a Definitive Asset Purchase Agreement With Ayala Pharmaceuticals to Acquire AL102 and AL101 Drug Candidates
Moomoo 24/7Feb 6 15:38 ET
Immunome Shares Rise 16% After Acquisition of Potential Tumor Treatment From Ayala Pharmaceuticals
By Chris Wack Immunome shares were up 16% to $19.56 after the company agreed to buy AL102 and related drug candidate AL101 from Ayala Pharmaceuticals. Ayala shares more than doubled to $1.31 in rece
WSJFeb 6 10:53 ET
Immunome to Buy AL102, a Phase 3 Asset for Treatment of Desmoid Tumors
Seeking AlphaFeb 6 08:14 ET
Immunome Will Pay Ayala $20M in Cash and $30M in Immunome Common Stk at the Closing and Will Pay Up to an Additional $37.5M in Development and Comml Milestone Payments >IMNM
Immunome Will Pay Ayala $20M in Cash and $30M in Immunome Common Stk at the Closing and Will Pay Up to an Additional $37.5M in Development and Comml Milestone Payments >IMNM
Dow JonesFeb 6 08:01 ET
Immunome Entered Into a Definitive Asset Purchase Agreement With Ayala Pharmaceuticals to Acquire AL102 and Related Drug Candidate AL101 From Ayala >IMNM
Immunome Entered Into a Definitive Asset Purchase Agreement With Ayala Pharmaceuticals to Acquire AL102 and Related Drug Candidate AL101 From Ayala >IMNM
Dow JonesFeb 6 08:00 ET
Advaxis Cut to Neutral From Buy by Ladenburg Thalmann
Advaxis Cut to Neutral From Buy by Ladenburg Thalmann
Dow JonesNov 16, 2023 14:22 ET
Ladenburg Thalmann Downgrades Ayala Pharmaceuticals to Neutral
Ladenburg Thalmann analyst Ahu Demir downgrades Ayala Pharmaceuticals (OTC:ADXS) from Buy to Neutral.
BenzingaNov 16, 2023 14:12 ET
Ayala Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/16/2023 — Ladenburg Thalmann Downgrades Buy → Neutral 05/30/2023 450.74% Ladenburg Thalmann → $4 Upgra
BenzingaNov 16, 2023 14:11 ET
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Dr
GlobeNewswireNov 6, 2023 08:00 ET
Ayala Pharmaceuticals Presents Updated AL102 Results From Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity
GlobeNewswireOct 23, 2023 07:00 ET
Ayala Pharmaceuticals Announces Closing Of Merger With Biosight >ADXS
Ayala Pharmaceuticals Announces Closing Of Merger With Biosight >ADXS
Dow JonesOct 19, 2023 08:00 ET
Advaxis GAAP EPS of -$1.82 Beats by $0.37
Seeking AlphaAug 10, 2023 17:19 ET
Press Release: Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enr
Dow JonesAug 10, 2023 16:39 ET
Desmoid Tumors Market Report, 2023: Key Players in the Field - Ayala Pharmaceuticals, SpringWorks Therapeutics, Recursion Pharmaceuticals, and More
DUBLIN, Aug. 1, 2023 /PRNewswire/ -- The "Desmoid Tumors - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights into the
PR NewswireAug 1, 2023 18:45 ET
No Data
No Data